Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Veracyte (Nasdaq: VCYT) will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Veracyte (Nasdaq: VCYT) will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time. A live audio webcast and a 90-day replay will be accessible via the company’s investor relations website.
Details
News Market Reaction – VCYT
On Sep 2, the first trading day after this news, VCYT closed 3.50% above the previous close. Our momentum scanner recorded 10 alerts for this stock that day. Relative volume reached 2.8x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 2 session.
Key Figures
- Conference edition
- 24th
- Morgan Stanley Global Healthcare Conference
- Presentation date
- September 15, 2026
- Fireside chat
- Presentation time
- 7:00 a.m. Eastern Time
- September 15, 2026
- Webcast replay
- 90 days
- After the live presentation broadcast
Historical Context
-
Revenue growth, profitability and raised full-year guidance were followed by a negative reaction.
-
The company announced participation in two upcoming investor conference fireside chats.
-
Veracyte scheduled its second-quarter results release and accompanying conference call.
-
Veracyte announced the U.S. commercial launch of its Prosigna Breast Test.
-
OPTIMA results reported chemotherapy avoidance alongside comparable five-year cancer-free survival.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
A live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days after the live presentation broadcast.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter).
Investors:
Kelly Gura
investors@veracyte.com
Media:
Molly Cornbleet
media@veracyte.com
+1-650-351-8780
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.